Data Insights

DZD-8586 by Dizal Pharmaceutical for Follicular Lymphoma: Likelihood of Approval

DZD-8586 is under clinical development by Dizal Pharmaceutical and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - DZD-8586 in Follicular Lymphoma

Data Insights

DZD-8586 by Dizal Pharmaceutical for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

DZD-8586 is under clinical development by Dizal Pharmaceutical and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According...

Likelihood of Approval and Phase Transition Success Rate Model - DZD-8586 in Refractory Chronic Lymphocytic Leukemia (CLL)

Data Insights

DZD-8586 by Dizal Pharmaceutical for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

DZD-8586 is under clinical development by Dizal Pharmaceutical and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL). According...

Likelihood of Approval and Phase Transition Success Rate Model - DZD-8586 in Relapsed Chronic Lymphocytic Leukemia (CLL)

Data Insights

DZD-8586 by Dizal Pharmaceutical for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

DZD-8586 is under clinical development by Dizal Pharmaceutical and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - DZD-8586 in B-Cell Non-Hodgkin Lymphoma

Data Insights

DZD-8586 by Dizal Pharmaceutical for Marginal Zone B-cell Lymphoma: Likelihood of Approval

DZD-8586 is under clinical development by Dizal Pharmaceutical and currently in Phase II for Marginal Zone B-cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - DZD-8586 in Marginal Zone B-cell Lymphoma

Data Insights

Golidocitinib by Dizal Pharmaceutical for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval

Golidocitinib is under clinical development by Dizal Pharmaceutical and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Golidocitinib in Peripheral T-Cell Lymphomas (PTCL)

Data Insights

Golidocitinib by Dizal Pharmaceutical for Sezary Syndrome: Likelihood of Approval

Golidocitinib is under clinical development by Dizal Pharmaceutical and currently in Phase II for Sezary Syndrome. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Golidocitinib in Sezary Syndrome

Data Insights

Golidocitinib by Dizal Pharmaceutical for Cutaneous T-Cell Lymphoma: Likelihood of Approval

Golidocitinib is under clinical development by Dizal Pharmaceutical and currently in Phase II for Cutaneous T-Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Golidocitinib in Cutaneous T-Cell Lymphoma

Data Insights

Golidocitinib by Dizal Pharmaceutical for Unspecified Immunological Disorders: Likelihood of Approval

Golidocitinib is under clinical development by Dizal Pharmaceutical and currently in Phase I for Unspecified Immunological Disorders. According to GlobalData,...